Ruth de Tute

3.5k total citations
28 papers, 871 citations indexed

About

Ruth de Tute is a scholar working on Genetics, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Ruth de Tute has authored 28 papers receiving a total of 871 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Genetics, 14 papers in Pathology and Forensic Medicine and 11 papers in Oncology. Recurrent topics in Ruth de Tute's work include Chronic Lymphocytic Leukemia Research (17 papers), Lymphoma Diagnosis and Treatment (14 papers) and Multiple Myeloma Research and Treatments (10 papers). Ruth de Tute is often cited by papers focused on Chronic Lymphocytic Leukemia Research (17 papers), Lymphoma Diagnosis and Treatment (14 papers) and Multiple Myeloma Research and Treatments (10 papers). Ruth de Tute collaborates with scholars based in United Kingdom, United States and Uganda. Ruth de Tute's co-authors include Andy C. Rawstron, Andrew Jack, Peter Hillmen, Fiona Bennett, Marieth Plummer, Roger G. Owen, Stephen J. Richards, James A. L. Fenton, Marwan Kwok and Sheila J.M. O’Connor and has published in prestigious journals such as Nature, New England Journal of Medicine and Journal of Clinical Oncology.

In The Last Decade

Ruth de Tute

24 papers receiving 860 citations

Peers

Countries citing papers authored by Ruth de Tute

Since Specialization

Citations

This map shows the geographic impact of Ruth de Tute's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruth de Tute with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruth de Tute more than expected).

Fields of papers citing papers by Ruth de Tute

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruth de Tute. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruth de Tute. The network helps show where Ruth de Tute may publish in the future.

Co-authorship network of co-authors of Ruth de Tute

This figure shows the co-authorship network connecting the top 25 collaborators of Ruth de Tute. A scholar is included among the top collaborators of Ruth de Tute based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruth de Tute. Ruth de Tute is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Excised DNA circles from V(D)J recombination promote relapsed leukaemia 2025 ·Nature ·(unknown), James N. Scott, Matthew Edwards, (unknown), Xiaoling Wang, (unknown), Sarra Ryan, Lisa J. Russell, Anthony V. Moorman, Ruth de Tute, Catherine Cargo, Anthony M. Ford, David R. Westhead, Joan Boyes	0
2	Optimising MRD-guided treatment: UMRD4 as a half-way treatment timepoint for ibrutinib-venetoclax substantially delays MRD relapse after end of treatment in both IGHV-mutated and IGHV-unmutated CLL. 2025 ·Blood ·Andy C. Rawstron, David Cairns, Nichola Webster, Surita Dalal, (unknown), Ruth de Tute, Anna Hockaday, Sharon Jackson, Sue Bell, (unknown), David Stones, David Allsup, Adrian Bloor, Anita Sarma, Abraham Varghese, Talha Munir, Peter Hillmen	0
3	Acquired Bruton's tyrosine kinase mutations in patients treated on the ibrutinib and rituximab, ibrutinib alone, and ibrutinib and venetoclax arms of the national multi-centre Phase III FLAIR study in previously untreated CLL patients 2025 ·Blood ·(unknown), Surita Dalal, Darren Newton, (unknown), Nichola Webster, Andy C. Rawstron, Ruth de Tute, Anna Hockaday, Sharon Jackson, Sue Bell, (unknown), David Stones, David Allsup, Adrian Bloor, Anita Sarma, (unknown), Peter Hillmen, (unknown)	0
4	PembroWM : A phase II trial to investigate the safety and efficacy of rituximab and pembrolizumab in relapsed/refractory Waldenström's Macroglobulinaemia 2024 ·British Journal of Haematology ·Jaimal Kothari, Toby A. Eyre, Ali Rismani, (unknown), (unknown), (unknown), William Wilson, (unknown), Laura Clifton‐Hadley, Helen O. McCarthy, Angela Collins, David Lewis, (unknown), Rebecca Auer, Guy Pratt, Ruth de Tute, Roger G. Owen, Shirley D’Sa	3
5	Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometry 2024 ·Blood Cancer Journal ·(unknown), Mark T. Drayson, Bhuvan Kishore, Charlotte Pawlyn, Martin Kaiser, Gordon Cook, Ruth de Tute, Roger G. Owen, David A. Cairns, (unknown), Faith E. Davies, Gareth J. Morgan, Guy Pratt, Graham Jackson	3
6	Long-term outcomes by bone marrow B-cell depletion from the R2W trial of bortezomib with cyclophosphamide and rituximab in Waldenstrőm macroglobulinaemia 2024 ·Leukemia ·Ruth de Tute, Nicholas Counsell, Laura Clifton‐Hadley, Shirley D’Sa, Guy Pratt, Gavin Campbell, (unknown), Ross Sadler, William Townsend, Bilyana Popova, Paul Smith, (unknown), Roger G. Owen, Rebecca Auer	0
7	Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial 2024 ·The Lancet Haematology ·Gordon Cook, A. John Ashcroft, (unknown), Catherine Olivier, Anna Hockaday, (unknown), Jamie Cavenagh, John A. Snowden, Mark T. Drayson, Ruth de Tute, (unknown), Roger G. Owen, Kwee Yong, Mamta Garg, Kevin Boyd, Hamdi Sati, (unknown), Mark Cook, David A. Cairns, Christopher Parrish	1
8	Lymphoid blood cancers, incidence and survival 2005-2023: A report from the UK’s Haematological Malignancy Research Network 2023 ·Cancer Epidemiology ·Maxine Lamb, Daniel Painter, Debra Howell, Sharon Barrans, Catherine Cargo, Ruth de Tute, Reuben Tooze, Cathy Burton, Russell Patmore, Eve Roman, Alexandra Smith	10
9	Health impact of monoclonal gammopathy of undetermined significance (MGUS) and monoclonal B-cell lymphocytosis (MBL): findings from a UK population-based cohort 2021 ·BMJ Open ·Maxine Lamb, Alexandra Smith, Daniel Painter, Eleanor Kane, (unknown), Robert Newton, Debra Howell, Gordon Cook, Ruth de Tute, Andy C. Rawstron, Russell Patmore, Eve Roman	6
10	Depth of response and minimal residual disease status in ultra high-risk multiple myeloma and plasma cell leukemia treated with daratumumab, bortezomib, lenalidomide, cyclophosphamide and dexamethasone (Dara-CVRd): Results of the UK optimum/MUKnine trial. 2021 ·Journal of Clinical Oncology ·Martin Kaiser, Andrew Hall, Katrina Walker, Ruth de Tute, (unknown), Emma Ingleson, Kristian M. Bowles, Mamta Garg, Anand Lokare, Christina Messiou, Graham Jackson, Guy Pratt, Gordon Cook, Mark T. Drayson, Roger G. Owen, Sarah Brown, Matthew Jenner	11
11	TLR-mediated activation of Waldenström macroglobulinemia B cells reveals an uncoupling from plasma cell differentiation 2020 ·Blood Advances ·(unknown), Matthew A. Care, (unknown), (unknown), Paul Evans, (unknown), Ruth de Tute, Roger G. Owen, Reuben Tooze, Gina M. Doody	4
12	Minimal residual disease (MRD) in Waldenström macroglobulinaemia (WM): Impact on survival outcomes with rituximab-based therapies. 2019 ·Clinical Lymphoma Myeloma & Leukemia ·Ruth de Tute, Andy C. Rawstron, Shirley D’Sa, Guy Pratt, Laura Clifton‐Hadley, (unknown), Nicholas Counsell, Rebecca Auer, Roger G. Owen	1
13	Assessment of plasma cell myeloma minimal residual disease testing by flow cytometry in an international inter‐laboratory study: Is it ready for primetime use? 2018 ·Cytometry Part B Clinical Cytometry ·(unknown), Matthew Fletcher, Helen Whitehouse, Liam Whitby, Constance M. Yuan, (unknown), Pei Lin, Ruth de Tute, (unknown), Paul K. Wallace, Prashant Tembhare, Maria Arroz, John A. Snowden, Andrew Chantry, David Barnett	5
14	Monoclonal B-cell lymphocytosis in a hospital-based UK population and a rural Ugandan population: a cross-sectional study 2017 ·The Lancet Haematology ·Andy C. Rawstron, Aloysius Ssemaganda, Ruth de Tute, (unknown), Darren Newton, Anna Vardi, Paul Evans, Κώστας Σταματόπουλος, Roger G. Owen, Tracy Lightfoot, Katie Wakeham, Alex Karabarinde, Gershim Asiki, Robert Newton	10
15	The LLR TAP IcICLLe Trial: detailed assessment of the response to ibrutinib provides insights into the mode of action and pattern of response in treatment nayve and refractory CLL. 2015 ·Andy C. Rawstron, (unknown), (unknown), Surita Dalal, Ruth de Tute, Kristian Brock, Francesca Yates, Adrian Bloor, Julie Fox, Chris Fegan, D. Blair Macdonald, Peter Hillmen	1
16	FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma 2012 ·Molecular Cancer Therapeutics ·Kristi Elkins, Bing Zheng, MaryAnn Go, Dionysos Slaga, Changchun Du, Suzie J. Scales, Shang‐Fan Yu, Jacqueline McBride, Ruth de Tute, Andy C. Rawstron, Andrew Jack, Allen Ebens, Andrew G. Polson	69
17	Chronic lymphocytic leukaemia (CLL) and CLL‐type monoclonal B‐cell lymphocytosis (MBL) show differential expression of molecules involved in lymphoid tissue homing 2010 ·Cytometry Part B Clinical Cytometry ·Andy C. Rawstron, (unknown), Ruth de Tute, Fiona Bennett, Andrew Jack, Peter Hillmen	26
18	Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia 2008 ·New England Journal of Medicine ·Andy C. Rawstron, Fiona Bennett, Sheila J.M. O’Connor, Marwan Kwok, James A. L. Fenton, Marieth Plummer, Ruth de Tute, Roger G. Owen, Stephen J. Richards, Andrew Jack, Peter Hillmen	371
19	B‐cell chronic lymphocytic leukaemia cells show specific changes in membrane protein expression during different stages of cell cycle 2007 ·British Journal of Haematology ·Fiona Bennett, Andy C. Rawstron, Marieth Plummer, Ruth de Tute, Paul Moreton, Andrew Jack, Peter Hillmen	29
20	Flow cytometric protein expression profiling as a systematic approach for developing disease-specific assays: identification of a chronic lymphocytic leukaemia-specific assay for use in rituximab-containing regimens 2006 ·Leukemia ·Andy C. Rawstron, Ruth de Tute, Andrew Jack, Peter Hillmen	33

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact